Immunocore’s Gates injection

A $40 million investment from the Bill & Melinda Gates Foundation will allow Immunocore Ltd. to pursue parallel development of multiple immunotherapies in infectious diseases, an area the T cell receptor company had already been expanding over the past 18 months.

According to Kevin Pojasek, Immunocore VP and director of corporate strategy and co-head of its infectious disease unit, the Gates money will be ring-fenced for development of the biotech’s two infectious disease platforms: Immune mobilising monoclonal TCRs against virus (ImmTAV) and immune mobilising monoclonal TCRs against bacteria (ImmTAB). ...